Skip to content
Sign in
Artwork for The Regulatory Mix
Business

The Regulatory Mix

Tailwind Pharma LLC

The Regulatory Mix uses AI hosts to break down the latest FDA guidance, enforcement trends, CGMP expectations, drug-manufacturing issues, and emerging regulatory developments—without the jargon. Episodes are curated by former FDA investigator and compliance officer Joseph Lambert, PharmD, to provide practical insights for pharmaceutical quality, compliance, and industry professionals. For historical episodes and the full archive, visit Apple Podcasts: https://podcasts.apple.com/us/podcast/the-regulatory-mix/id1772132994

Play
Open in
  • 7 episodes
  • a few times a week
  • Avg 20 min
  • English

Episodes 7

NewestOldestLongest
All7Unplayed7In progress0Played0
  • Sunday · 19 min

    The GLP-1 Compounding Crackdown: FDA Draws the Line on “Essentially a Copy”

    On this episode of The Regulatory Mix, the discussion turns to FDA’s intensifying scrutiny of compounded GLP-1 medications and what the September 2026 Empower Pharmacy Warning Letter may signal for the broader compounding industry. During the semaglutide and tirzepatide shortages, compounding filled an important supply gap. But with those shortages resolved, FDA is applying much greater scrutiny to whether compounded products meet the statutory conditions of section 503A. At the center of the issue is a deceptively simple question: when does a customized formulation represent a legitimate patient-specific need, and when is it merely an “essentially identical” copy of an FDA-approved drug? The Empower case highlights that adding ingredients such as cyanocobalamin or niacinamide does not automatically establish a clinically significant difference. FDA focused on whether prescribers actually documented an individualized need for the modified formulation and whether repeated, standardized rationales across large numbers of prescriptions reflected genuine clinical judgment or something closer to mass production. That brings telehealth and automated prescribing workflows directly into the compliance discussion. Pre-populated checkboxes, required fields, and standardized “significant difference” language may improve workflow efficiency, but they can also undermine the individualized prescribing foundation on which section 503A relies. High production volumes combined with repeated identical justifications may become powerful compliance signals for FDA investigators. The episode also examines what happens when a compounder falls outside the conditions of section 503A. The consequences can move quickly beyond documentation deficiencies. Products may lose statutory exemptions and become subject to requirements involving approved applications, labeling, and CGMP. In the Empower case, FDA’s concerns also extended into aseptic processing, media fills, smoke studies, environmental monitoring, Quality Unit oversight, and data integrity. And the patient-safety issue goes beyond the manufacturing suite. Compounded GLP-1 products supplied in multidose vials can introduce dosing complexity that does not exist with many commercial pen products. Confusion between milligrams, milliliters, concentrations, and syringe “units” has contributed to significant dosing errors, reinforcing why labeling, formulation, dispensing, and patient instructions are all part of the risk equation. The takeaway is that the shortage-era environment is ending. For compounders, telehealth providers, and prescribers, GLP-1 compliance is increasingly about demonstrating that customization is genuinely patient-specific, clinically meaningful, and supported by defensible records. Adding a vitamin, checking a box, or repeating a standardized rationale is unlikely to substitute for individualized clinical judgment. FDA Warning Letter: Empower Clinic Services, LLC dba Empower Pharmacy, Warning Letter No. 738238, issued September 18, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026 Disclosure: Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

  • September 20 · 20 min

    Are CRLs Really Rising? FDA’s 16-Year Data Say Otherwise

    On this episode of The Regulatory Mix, the discussion takes a closer look at first-cycle Complete Response rates for CDER New Drug Applications and Biologics License Applications from FY 2008 through FY 2024. Recent industry commentary has suggested that Complete Response rates are structurally increasing. FDA’s own longitudinal analysis paints a more nuanced picture. The first-cycle CR rate for original NDAs and BLAs declined from approximately 47% in FY 2008 to about 27% in FY 2024. After a significant downward shift around FY 2011, rates largely stabilized around the 30% range rather than continuing on a sustained upward trajectory. (U.S. Food and Drug Administration⁠) The episode also explores why methodology matters when discussing approval statistics. Product-level approval data and submission-level PDUFA data are not interchangeable, and receipt cohorts can take multiple fiscal years to mature. Depending on the denominator, time period, and unit of analysis selected, very different narratives can emerge from what appears to be the same regulatory dataset. One of the most important findings is that a first-cycle Complete Response is not the same as ultimate failure. Across the period analyzed, the median first-cycle approval rate was approximately 64%, while roughly 77% of those original NDA and BLA applications are now in approved status after subsequent review cycles. (U.S. Food and Drug Administration⁠) The takeaway is that year-to-year fluctuations can generate headlines, but long-term data provide a better view of regulatory performance. The FDA analysis suggests that Complete Response rates are not on a persistent upward path and that many applications receiving an initial CR ultimately reach approval after deficiencies are addressed. For industry, the more useful question may not be whether CR rates are rising, but what separates applications that achieve first-cycle approval from those that require another round of review. Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client. Source:FDA Report: First-Cycle Complete Response Rates for CDER NDA and BLA Applications: A Longitudinal Analysis, FY 2008–2024 https://www.fda.gov/media/194858/download

  • September 16 · 21 min

    AI, CGMP, and the Cost of Over-Reliance

    On this episode of The Regulatory Mix, we examine the growing intersection of artificial intelligence, pharmaceutical manufacturing, and regulatory accountability. As AI moves deeper into Current Good Manufacturing Practice environments, the key question is not whether firms will use it, but whether they can do so without weakening quality oversight, critical thinking, and compliance discipline. A recent FDA Warning Letter to Purolea Cosmetics Lab provides a clear example of what can go wrong when AI is used without meaningful human review. The firm relied on AI to generate product specifications, procedures, and production records, while basic CGMP responsibilities were not adequately understood or controlled. FDA specifically criticized the lack of Quality Unit oversight and the firm’s failure to recognize process validation requirements. The episode also looks at FDA’s emerging risk-based framework for evaluating AI credibility. The level of assurance required depends on three key factors: the model’s context of use, how much influence it has on a decision, and the consequence if that decision is wrong. The greater the model’s role and the higher the patient or product risk, the stronger the expectation for validation and oversight. Beyond compliance, the discussion turns to the effect of generative AI on human judgment. Research involving knowledge workers suggests that AI can shift cognitive effort away from direct problem-solving and toward verification and supervision. That can improve efficiency, but it also creates risks such as automation bias, reduced independent thinking, and skill atrophy when users become overly dependent on machine-generated outputs. The takeaway is simple: AI can assist regulated work, but it cannot assume regulatory responsibility. Accountability remains with the firm, the Quality Unit, and the qualified individuals responsible for ensuring that every decision affecting product quality and patient safety is scientifically sound and compliant. Reference Links: Purolea Cosmetics Lab Warning Letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purolea-cosmetics-lab-722591-04022026 FDA Draft Guidance on AI Model Credibility: https://www.fda.gov/media/184830/download Research: AI and Critical Thinking https://www.microsoft.com/en-us/research/wp-content/uploads/2025/01/lee_2025_ai_critical_thinking_survey.pdf Disclaimer: The views expressed in this episode are personal opinions for educational purposes only and do not constitute legal, regulatory, or medical advice.

  • September 13 · 20 min

    2(b) or Not 2(b)? FDA’s 2026 Sequel to the ANDA vs. 505(b)(2) Debate

    On this episode of The Regulatory Mix, the discussion revisits one of the most consequential strategic choices in drug development: whether a product belongs in a 505(j) ANDA or a 505(b)(2) application. FDA’s revised 2026 draft guidance, Determining Whether to Submit an ANDA or a 505(b)(2) Application, reads almost like a sequel to the Agency’s earlier framework—same core question, but with a more direct regulatory message: choose the pathway carefully, engage early, and do not assume flexibility where FDA believes an ANDA route is still scientifically available. The episode explores several important updates, including FDA’s more assertive direction to prospective applicants to engage the Office of Generic Drugs before committing to a development strategy. That matters most where a Reference Listed Drug has been discontinued, because the absence of a traditional reference standard does not automatically open the door to 505(b)(2). If FDA identifies an acceptable alternative method to establish bioequivalence, the Agency may still view 505(j) as the appropriate pathway and refuse to file a 505(b)(2) application. The discussion also covers the evolving therapeutic equivalence landscape. The 2026 draft reflects newer mechanisms that may allow certain 505(b)(2) applicants to request a therapeutic equivalence determination without relying solely on the traditional citizen petition process. That could have meaningful implications for pharmacy substitution, commercial uptake, and lifecycle strategy, particularly where the only difference from the reference product involves excipients that would not fit within standard ANDA requirements. Another important theme is that pathway selection is not simply a legal classification exercise. It affects development cost, clinical requirements, labeling strategy, patent and exclusivity considerations, substitution potential, and time to market. A decision that looks efficient early in development can become expensive very quickly if FDA determines that the application was built on the wrong statutory foundation. The broader takeaway is that FDA appears to be encouraging a conversation before the commitment. The revised guidance makes clear that sponsors should not treat ANDA versus 505(b)(2) as a late-stage filing decision. It is an early development strategy question that should be resolved before significant resources are committed to formulation work, bioequivalence studies, clinical programs, or commercial planning. Or, in Hamlet’s terms: 2(b), or not 2(b), really is the question—but FDA would prefer you ask before you spend the money. Reference link: https://www.fda.gov/media/160054/download Disclosure: Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

  • September 9 · 20 min

    The 30-Year Plant, the 3-Year Forecast: Pharma’s Infrastructure Risk Problem

    On this episode of The Regulatory Mix, the discussion focuses on a growing strategic problem across the pharmaceutical industry: companies are making 20- and 30-year infrastructure investments in a world where demand forecasts, technologies, regulations, and geopolitical assumptions can change in only a few years. The episode examines major investments in peptide, API, and antibiotic manufacturing as companies race to secure capacity and reduce supply-chain dependence. Projects from Bachem, Aurobindo, and other manufacturers demonstrate the scale of the bet being made on future demand. But the strategic question is no longer simply whether additional capacity is needed. It is whether today’s highly specialized assets will still be commercially and technologically relevant by the time they are fully validated and operating at scale. That tension is becoming more important as regulators increase their focus on supply-chain resilience. In Europe, shortage prevention planning is placing greater responsibility on marketing authorization holders to understand vulnerabilities before a disruption occurs. In the United States, FDA organizational changes and continued updates to product-specific guidance reflect an environment in which regulatory expectations can evolve far faster than physical manufacturing infrastructure. The discussion also highlights why supply resilience cannot be separated from manufacturing quality. Recent FDA findings at sterile manufacturing facilities demonstrate the danger of allowing business urgency to override process understanding. Passing sterility tests, environmental monitoring, or final product testing does not compensate for recurring contamination events or weak investigations. Sterility assurance remains fundamentally process-based, and repetitive deviations that are explained away rather than understood can become evidence of a much larger quality-system failure. The same principle applies at the boardroom level. Organizations can create strategic risk when assumptions become progressively more optimistic simply to justify a major capital project or acquisition. Leadership teams should continually challenge which assumptions would leave the organization trapped if demand changes, a new modality emerges, regulations shift, or a competitor develops a fundamentally easier manufacturing route. The takeaway is that pharmaceutical resilience is no longer just about building more capacity. It is about building adaptable capacity supported by strong quality systems, diversified supply chains, regulatory awareness, and the ability to change direction before yesterday’s strategic advantage becomes tomorrow’s stranded asset. Disclosure: Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

  • August 30 · 17 min

    Will 503B Go to the Dogs? FDA’s New Framework for Compounded Animal Drugs

    On this episode of The Regulatory Mix, the discussion turns to FDA’s draft Guidance for Industry #256B and a potentially significant expansion of the animal drug compounding landscape. The draft guidance addresses animal drugs compounded from bulk drug substances at federally registered facilities, including establishments registered under sections 503B(b) and 510(b) of the FD&C Act. The most important message is that FDA may exercise enforcement discretion for certain statutory requirements surrounding animal drug compounding, but it does not generally intend to extend that discretion to current good manufacturing practice violations. For federally registered facilities, compounded animal drugs from bulk substances would still be expected to be manufactured under CGMP. That distinction could be particularly important for 503B outsourcing facilities considering entry into the veterinary market. FDA’s concern is that allowing one portion of a registered facility to operate under CGMP while another produces drugs under a lower quality standard could create problems for inspections, regulatory clarity, and customer expectations regarding product quality. The draft also addresses facilities that may operate under both federal registration and state pharmacy authorities. If a facility intends to compound some animal drugs under the traditional pharmacy framework while producing others under the federally registered pathway, FDA expects clear segregation between those operations. Products not manufactured under CGMP would also need to be clearly distinguished so they are not confused with drugs produced under the facility’s federally registered operations. The broader implication is that this could create a new opportunity for outsourcing facilities already equipped with mature quality systems, validated processes, environmental controls, and CGMP infrastructure. But it is not simply a matter of adding veterinary products to an existing portfolio. Firms will need to understand the regulatory pathway, state-law implications, operational segregation requirements, labeling considerations, and the quality-system expectations that come with manufacturing inside a federally registered establishment. The takeaway is that FDA appears willing to create a pathway for broader animal drug compounding from bulk substances—but not at the expense of CGMP. For 503B facilities looking for new markets, the veterinary space may offer an opportunity, but the quality bar is not being lowered just because the patient has four legs. Disclosure: Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client. Source: FDA Draft Guidance for Industry #256B, Compounding Animal Drugs from Bulk Drug Substances in Federally-Registered Facilities https://www.fda.gov/media/194414/download

  • #102
    August 28 · 20 min

    The AI Validation Divide: FDA Flexibility vs. EU Control in GxP Systems

    On this episode of The Regulatory Mix, the discussion focuses on one of the most difficult questions facing regulated life sciences: how do you validate a system that may not give you the exact same answer twice? As generative AI and machine learning move deeper into pharmaceutical, medical device, and GxP environments, regulators are beginning to take different approaches to managing that uncertainty. The emerging U.S. approach places greater emphasis on demonstrated performance, predefined acceptance criteria, benchmarking, real-world monitoring, and continued assessment for model drift. The European approach reflected in developing Annex 22 expectations is more conservative for critical GMP applications, emphasizing static or locked models, reproducibility, and strong limitations on the use of generative AI where outputs could directly affect product quality or patient safety. The episode explores why this distinction matters. Traditional computerized system validation was built largely around deterministic software: defined inputs, expected outputs, and repeatable test results. Large language models challenge that paradigm because variability is inherent to the technology. The regulatory question therefore becomes whether reproducibility must be designed into the architecture itself or whether variability can instead be characterized, bounded, monitored, and controlled statistically. The discussion also examines the proposed modernization of EU GMP Annex 11 and what it means beyond AI. Lifecycle validation, Quality Risk Management, requirements traceability, data integrity, access controls, supplier oversight, change management, and continued validated-state maintenance remain foundational expectations regardless of the technology being deployed. Using a cloud provider, commercial AI platform, or third-party foundation model does not transfer regulatory accountability away from the regulated company. Human oversight is another central issue. A person approving an AI output is not necessarily an effective control if that individual lacks the domain knowledge or AI literacy needed to recognize when the system is wrong. Meaningful human-in-the-loop oversight therefore requires both technical understanding and subject-matter expertise, as well as awareness of automation bias and the natural tendency to trust confident machine-generated answers. The takeaway is that AI does not eliminate traditional validation principles—it puts pressure on them. The industry now has to determine how concepts such as intended use, risk, traceability, change control, supplier qualification, data integrity, and continued verification apply to systems whose behavior may be probabilistic rather than fixed. The firms that solve this problem will not simply be the ones adopting AI fastest, but those that can demonstrate that its variability is understood, controlled, and appropriate for its intended GxP use. Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

Showing 1–7 of 7 episodes